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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of 
the metabolic syndrome and has a complex pathophysiology with multiple 
pathways of development and progression implicated. Intestinal hormones 
regulate multiple biological functions and may play a role in the pathogenesis of 
non alcoholic fatty liver disease (NAFLD) by affecting food intake, body weight 
and insulin resistance. Bacterial products can affect the secretion of these 
hormones and thus have an effect on metabolism. Gut microbiota are normally 
involved in the intestinal energy harvest and their role has been increasingly 
been implicated in the pathogenesis of obesity and NAFLD. The intestinal 
hormone pathways as well as in the intestinal microbiota populations are 
potential therapeutic targets in the management of NAFLD. We review the 
evidence on the associations of the intestinal hormones and gut microbiota in the 
development, progression and treatment of NAFLD. 
 
 
  
Introduction 
Nonalcoholic fatty liver disease (NAFLD) is defined as the accumulation of 
fat in the liver of patients who do not consume excessive alcohol (1). It is the 
most common hepatic disease and depending on the population and the 
diagnostic methods that have been used has a prevalence of up to 35% (2). 
NAFLD is the hepatic manifestation of the metabolic syndrome and is usually 
associated with central obesity, dyslipidemia, insulin resistance and diabetes (3, 
4). In terms of pathology, NAFLD includes two separate entities: non alcoholic 
fatty liver (NAFL) which is the accumulation of fat defined by the presence of 
steatosis in >5% of hepatocytes (‘fatty liver’ or steatosis) with no inflammation or 
fibrosis and non alcoholic steatohepatitis (NASH). The latter requires the joint 
presence of steatosis, ballooning and lobular inflammation, carries a worse 
prognosis and might be associated with fibrosis, cirrhosis and hepatocellular 
carcinoma (5).  
The pathogenesis of NAFLD is still unclear but appears to be multifactorial 
(1). Dietary factors including high calorie diet and high fructose intake as well as 
genetic factors have been implicated (5). In addition to these, the role of gut 
microbiota has been increasingly implicated over the last years as a possible 
factor contributing to NAFLD. The human gut contains an extensive number of 
microorganisms, known as the microbiota (6). The gut microbiota are important 
for several physiological functions including carbohydrate digestion, contribution 
of nutrients, vitamin biosynthesis, bile acid degradation and regulation of 
intestinal hormones (7). It consists of approximately 1011–1012 bacteria that 
reside in the colon, and 105–109 bacteria in the jejunum and ileum (8). In healthy 
adults, Bacteroidetes (mainly gram negative bacteria like Bacteroides fragilis) 
and Firmicutes (mainly gram positive clostridia), are the predominant phyla of the 
large intestine (9). However, there is a significant variability and each individual 
has a unique composition of microbes (8).  
The so-called liver–gut axis is the result of the tight anatomical connection 
between the liver and the gut. The liver receives 75% of its blood supply from the 
portal circulation; the blood flow originating from the intestines passes entirely 
through the liver where the necessary metabolic and immunologic processes 
take place before the blood finally flows to the systemic circulation (10). 
Therefore, the liver is exposed to the metabolic and inflammatory products of the 
intestinal bacteria that are transported there through the portal circulation. 
Multiple studies both in humans and animals have investigated the complex 
symbiotic relationship between the gut microbiota and the host. Available data 
indicate that there may be a possible causative role of microbiota in the 
development of obesity and NAFLD. Several mechanisms have been proposed 
and investigated.  
Intestinal hormones are produced by the entero-endocrine cells, in 
response to nutritional and hormonal signals and regulate multiple biological 
functions including food intake, gastric emptying, gut motility, gut barrier 
formation, and glucose metabolism (11). Bacterial products can also affect the 
secretion of these hormones and thus have an effect on metabolism. These 
hormones, may play a role in the NAFLD pathogenesis by affecting food intake, 
body weight and insulin resistance. Therefore, the metabolic pathway of the 
intestinal hormones has been the target not only for the treatment of diabetes but 
also for the treatment of NAFLD (11, 12).   
In this review we describe the role of intestinal hormones that are 
implicated in the pathogenesis of NAFLD and the therapeutic interventions in the 
intestinal hormone pathway that have been found to be useful in the treatment of 
this expression of the metabolic syndrome.  We also review the physiological 
aspects of the microbiota - human host symbiosis, the role of microbiota in 
energy harvest, intestinal hormone regulation and pathogenesis and treatment of 
NAFLD.  
 
Search strategy and selection criteria 
We searched Medline using the following search terms: “Intestinal 
hormones AND NAFLD” that indentified 66 results, “gut microbiota AND obesity”  
that indentified 1369 results and  “gut microbiota AND NAFLD” that revealed 179 
results. We largely included publications from the past 5 years, but we did not 
exclude highly relevant older publications. We also selected further relevant 
publications from the reference lists of articles identified by this search strategy. 
 
Intestinal hormones and NAFLD 
Multiple biological functions are physiologically regulated by gut hormones 
that are produced by the entero-endocrine cells, which consist about 1% of the 
intestinal cells (11). Among these, glucagon-like peptide 1 (GLP-1) has attracted 
the greater interest. GLP-1 is an incretin (i.e. an hormone that is released from 
the gut into the bloodstream in response to food ingestion) which is produced 
from the entero-endocrine cells in the distal small intestine and colon (13). The 
fasting plasma levels of GLP-1 increase approximately 2-3 folds reaching the 
peak levels about 20-30 minutes after a meal (13). The secretion of GLP-1 is 
mainly induced by nutritional elements like carbohydrates, lipids and proteins. 
Interestingly, it can also be induced by gut bacterial products: non digestible 
carbohydrates that reach the colon are metabolized by bacteria to short chain 
fatty acids (SCFA) like butyrate, propionate, and acetate which serve as an 
energy source to colonic epithelium (14). These bacteria-derived SCFA can also 
interact with the host and modify the levels of gut hormones that are produced by 
entero-endocrine cells and thus regulate energy homeostasis (11, 14). SCFA can 
activate selected G-protein-coupled receptors (GPCRs) on these cells and thus 
promote secretion of gut hormones like GLP-1 (13).  
GLP-1 is a significant hormone that has attracted great interest since it 
maintains glucose-dependent insulin secretion, promotes augmentation of b-cell 
mass in the pancreas and improves oral glucose tolerance and insulin sensitivity 
(11, 14). In addition, GLP-1 inhibits gastric emptying and GI motility, mainly via 
vagal nerve mediated mechanisms and also targets the brain by improving 
satiety and thus decreasing food intake (15, 16). Results from a randomized 
controlled trial that showed ultrasonographic improvement in patients with 
NAFLD taking a probiotic called VSL#3, showed that this benefit was mediated 
by GLP-1 increase (17). 
GLP-1 secretion may be also affected by hormonal factors since 
enterochromafine cells express receptors for hormones like insulin and leptin 
(13). Leptin is mainly produced by the adipose tissue and is involved in the 
pathogenesis of NASH by contributing to the development of insulin resistance 
and subsequently to steatosis (3). 
DPP-4 is an enzyme that degrades GLP-1 as well as other intestinal 
hormones like the gastric inhibitory polypeptide (GIP). The latter was the first 
isolated incretin which also induces insulin secretion (13). Commonly used anti-
diabetic drugs like sitagliptin belong to the category of DPP-4 inhibitors that 
maintain their antihyperglycemic action mainly by preventing the degradation of 
GLP-1. DPP-4 also metabolizes peptide tyrosine tyrosine (PYY). PYY is secreted 
postprandially mostly by the same intestinal L cells which also express GLP1. 
This hormone delays gastric emptying and has an anorectic effect (18). The 
potential role of DDP-4 inhibitors in NAFLD has not been extensively tested. In a 
mouse model, sitagliptin seemed to prevent the development of hepatic steatosis 
in animals fed with diet rich in sucrose and fatty acids (19). Some small trials in 
humans have shown some benefit in liver biochemistry and steatosis but 
there are no studies available that include histological data after DDP-4 
inhibition therapy (20). A recent randomized, double-blind, placebo-
controlled trial that included 50 NAFLD patients with pre-diabetes or early 
diabetes did not show any benefit of sitagliptin over placebo in reducing 
liver fat or improving liver biochemistry. This study assessed fat in liver 
with MRI-derived proton density-fat fraction and MR spectroscopy (21).  
Another category of antidiabetic drugs are the GLP-1R agonists which are 
resistant to DPP-4 inactivation. Liraglutide is probably the best studied drug for 
NAFLD that acts through the GLP-1 pathway. It is a long-acting GLP-1 analogue 
that has been licensed for glycaemic control in overweight patients with type 2 
diabetes (12) and for the treatment of obesity. A large meta-analysis of 
patients with type 2 diabetes and elevated liver enzymes treated with liraglutide 
showed an improvement in liver biochemistry (22), whereas a pilot study 
demonstrated that treatment with liraglutide had a good safety profile and 
significantly improved liver function and histological features in NASH patients 
(23). An important recent multicentre, double-blinded, randomized, placebo-
controlled trial assessed the safety and efficacy of liraglutide, in patients with 
NASH. Liraglutide given subcutaneously was found to be safe, well tolerated, 
and led to histological resolution of NASH, in 9 out of 26 patients in the drug 
group, compared to 2 out of 26 in the placebo group (12). On the contrary, a 
recently published placebo-controlled randomised trial that included 52 
patients and assessed the effects of a 12-week course of liraglutide or 
sitagliptin on spectroscopy-measured hepatic steatosis in patients with 
type 2 diabetes, did not show a significant effect on hepatic steatosis (24).  
The secretion of a similar peptide called glucagon-like peptide 2 (GLP-2) 
by the entero-endocrine cells can be also induced by bacteria derived SCFA. 
GLP-2 has been found to maintain the intestinal barrier by inducing intestinal 
epithelial cell proliferation and increasing the production of intestinal tight junction 
proteins (11). Prebiotic treated mice exhibited a decreased hepatic expression of 
inflammatory and oxidative stress markers. This decrease was associated with a 
lower intestinal permeability and improved tight-junction integrity compared to 
controls, which occurred in parallel with increased endogenous (GLP-2) 
production. Importantly, when the mice were given a GLP-2 antagonist, most of 
the prebiotic effects were abolished (25). 
Ghrelin is a gut hormone produced mainly by the stomach and the small 
intestine which has the opposite functions in basically all endocrine and 
metabolic target organs compared to GLP-1, as well as the opposite secretion 
patterns in response to food intake (16). Ghrelin is the only well-established 
peripherally produced orexigenic or hunger hormone and exerts its effect mainly 
through receptors in the central nervous system and possibly through afferent 
vagal mechanisms. It increases adiposity and decreases insulin secretion while 
stimulating glucagon secretion (16). In a study that included 75 morbidly obese 
patients with biopsy-proven NAFLD (41 of which had NASH), it was shown that 
patients with NASH had a two-fold higher concentration of des-acyl ghrelin than 
non-NASH patients (26). In addition, ghrelin concentrations in NASH patients 
with fibrosis stage ≥2 were almost double the concentration of NASH patients 
with fibrosis stage <2 indicating that the products of the ghrelin pathway may be 
important for the pathogenesis of NASH and fibrosis (26). The potential role of 
intestinal hormones in the pathogenesis of NASH is illustrated in Figure 1. 
 The role of gut microbiota in energy harvest and obesity 
 
The human intestinal microbiota has a symbiotic relationship with its host 
and contributes nutrients and energy by metabolizing dietary components in the 
large intestine. Non digestible carbohydrates of plant origin that reach the colon 
are metabolized by bacteria to SCFA like butyrate, propionate, and acetate 
which serve as an important energy source to colonic epithelium (14, 27).  
Microbiota derived butyrate enters the portal circulation and is transferred to the 
liver. There it enters the citric acid cycle via the production of acetyl-CoA and can 
thus enhance glycogen synthesis, decrease glucose oxidation and increase 
hepatic glycogen storage (14, 28).  As mentioned above, SCFA can induce 
insulin secretion and satiety through the GLP-1 pathway. Therefore, the role of 
SCFAs is somehow complex, since on the one hand they enhance energy 
harvest and contribute to excess lipogenesis in the liver, but on the other hand 
they concurrently increase insulin secretion and sensitivity, and enhance satiety 
(29). This depends on the particular SCFA; butyrate and propionate are 
considered predominantly anti-obesogenic. Butyrate is a major energy source for 
colonocytes but on the other hand improves insulin sensitivity, increases leptin 
expression, possess anti-inflammatory potential, increases intestinal barrier 
function and protects against diet-induced obesity (30). Propionate inhibits 
cholesterol synthesis, thereby antagonizing the cholesterol increasing action of 
acetate, and also inhibits the expression of resistin in adipocytes. Moreover, both 
these SCFAs have been found to cause weight regulation through their 
stimulatory effect on anorexigenic gut hormones and to increase the synthesis of 
leptin. On the other hand, acetate shows more obesogenic potential, as it acts as 
a substrate for synthesis of cholesterol and contributes in the synthesis of lipids 
in the liver (30). 
Turnbaugh et al showed that the microbiome from genetically obese mice 
has an increased capacity to harvest energy from the diet since they have 
significantly less energy remaining in their feces when compared to their lean 
littermates (31). Even more interesting was the finding that this trait was 
transmissible: colonization of germ-free mice with an ‘obese microbiome’ resulted 
in a significantly higher increase in total body fat than colonization with a ‘lean 
microbiome’ (31). Similarly, a recent study by Panasevich et al showed that the 
type of populations and the metabolic capacity of the microbiota in low-
aerobically fit rats may contribute to their susceptibility to acute high fat diet 
(HFD) induced hepatic steatosis (32). Low-aerobically fit rats had a greater 
propensity to gain weight and develop steatosis in response to an acute HFD 
compared with high-aerobically fit rats. It was suggested that the physiologic 
changes observed in the low-aerobically fit rats fed with an acute HFD 
appeared to be associated with decreases in SCFA-producing microbiota (32), 
A recent study by Chevalier et al suggested that intestinal energy harvest 
was increased during acute cold and that this increase contributed to maintaining 
stable body temperature. In parallel to this, exposure to cold resulted in marked 
changes in the composition of gut microbiota. Importantly, this shift in the 
bacterial composition was associated with an increase in energy harvest thus 
highlighting the role of gut microbiota in energy harvest and host homeostasis 
(33). Additionally, mice transplanted with ‘cold microbiota’ showed increased 
sensitivity to insulin, suggesting that ‘cold microbiota’ alone is sufficient to 
transfer part of the increased insulin sensitivity phenotype (33). 
Gut microbiota have been implicated in the development of obesity and 
thus contribute in the development of NAFLD. Available data from studies 
performed in mice support this hypothesis. Ley et al compared the microbiota of   
lean and obese mice and regardless of kinship, obese animals had a 50% 
reduction in the abundance of Bacteroidetes and a proportional increase in 
Firmicutes (34). Backhead et al found that exposure of adult germ-free mice to a 
normal microbiota originating from the distal intestine of conventionally raised 
animals resulted in a significant increase in body fat content and also in insulin 
resistance. Interestingly these results became apparent within days and occurred 
despite reduced food intake (6).  Duca et al demonstrated that obese prone (OP) 
and obese resistant (OR) mice phenotypes were associated with distinct and 
differing gut microbial communities only during high fat. Strikingly, phenotype and 
behavioral differences between OP and OR rats were reliably transferred to 
animals as long as they were on a high fat diet. OP as well as mice inoculated 
with OP microbiota had a significantly greater 24-h food intake and adiposity 
index than the others during HF feeding but not chow feeding. In addition, 
circulating leptin and insulin levels were significantly increased in OP recipient 
animals as were triglyceride and glycemia levels, features all associated with 
metabolic syndrome (35). Finally, on HF feeding but not on chow feeding, OP 
and the OP recipient animals both exhibited altered tight junction protein levels 
indicating an impaired mucosal barrier (35). 
Apart from increased energy harvest, a link between gut microbiota and 
obesity can be found in the impact that microbiota might have on appetite control. 
A recently published study by Breton et al suggested that E. Coli derived proteins 
may have a direct short-term effect on satiety by acting locally in the intestine. 
The release of gut hormones like GLP-1 and PYY could mediate this effect (36). 
In addition, the same study showed that bacterial derived proteins may also have 
a long term impact on the central control of appetite by activating central anorexic 
circuitries (36).  
Studies in humans have shown differences between obese and lean 
people with regard to the two dominant groups of bacteria that reside in their gut. 
The relative proportion of Bacteroidetes is decreased in obese people compared 
to lean people. This proportion, however, reverses with weight loss on low-calorie 
diet indicating that manipulation of gut microbial communities could be a possible 
approach in the treatment of obesity (37).  Nevertheless, there are several 
studies that found contradictive results with regard to the ratio of abundance of 
Firmicutes to Bacteroidetes (10). Scwiertz et al found that the ratio of Firmicutes 
to Bacteroidetes changed in favor of the Bacteroidetes in overweight and obese 
subjects (38). Hence, available data are still inconclusive and the question as to 
whether obesity alters the microbiome, or if the microbiome alters the risk for 
obesity remains and requires further long term research (10).  
An inpatient study that included 21 individuals showed that an altered nutrient 
load induced rapid changes in the bacterial composition of the human gut 
microbiota. During this study the amount of calories that were ingested and 
expelled in stool were measured. It was found that the alteration of the nutrient 
load induced a change in gut microbiota; it resulted in an increase in the 
abundance of Firmicutes and a corresponding decrease in Bacteroidetes which 
was associated with an increased energy harvest of approximately 150 Kcal (39) 
In an interesting study by Kalliomaki et al it was suggested that differences 
in the intestinal microbiota may precede the development of obesity. The 
abundance of Bifidobacteria in the first year of life was higher in children who had 
a normal weight at the age of seven compared to children who were overweight 
(40). 
 
Gut micorbiota and NAFLD 
 
Data from animal studies provide evidence that gut microbiota could be a 
causative factor for the development of NAFLD and that the gut microbiota-
mediated metabolic phenotype could be transmissible. A recent study by Le Roy 
et al showed that, germ-free mice that received intestinal bacteria from high 
blood glucose mice that were on a high-fat diet, were more likely to develop 
hepatic steatosis and insulin resistance compared to the subjects that were 
transplanted with bacteria from mice that although they were on a high fat diet as 
well, they had not developed high blood glucose levels (41, 42). Additionally, the 
results presented by Hanao Mejia et al provided evidence that modulation of the 
intestinal microbiota through multiple inflammasome components is a critical 
determinant of NAFLD/NASH progression. In the gut, the combination of host 
related factors including inflammasome deficiency-associated dysbiosis resulted 
in abnormal accumulation of bacterial products in the portal circulation like toll-
like receptors  (TLR) agonists whose influx into the portal circulation was 
sufficient to drive progression of NAFLD/NASH (43). Importantly, co-housing of 
inflammasome-deficient mice with wild-type mice resulted to the transmission of 
a NASH phenotype through the transmission of the microbiome (43). A study by 
Zeng et al, also performed in mice, showed that high fat feeding promotes certain 
predominant hind gut bacteria like Lactobacillus gasseri and/or Lactobacillus 
taiwanensis in addition to the development of NASH (44). 
NAFLD phenotypes have also been observed in humans; in a cohort of 61 
pediatric patients with NAFLD/NASH and 54 healthy controls, there were specific 
microbiota signatures associated with NAFLD onset and progression to NASH 
(45). A recent study found that an increased abundance of the Bacteroides 
genus was independently associated with NASH, and in addition, an increased 
abundance of the Ruminococcus genus was independently associated with 
fibrosis (46). Mouzaki et al showed that the percentage of Bacteroidetes was 
significantly lower in patients with biopsy proven NASH compared to healthy 
controls and subjects with NAFL. Interestingly, the low abundance of 
Bacteroidetes in NASH was independent of BMI and energy intake from fat 
indicating a possible causative factor of the type of microbiota in the development 
of NASH (47).  
A biochemical link has been suggested between bacteria derived volatile 
organic compounds and NASH. Recent findings from the study by Reid et al 
performed in mice showed that differences in portal venous bacteria derived 
volatile organic compounds levels were associated with diet-induced NASH  (48). 
An observational study did not only find differences in the type of microbiota 
between NAFLD and healthy volunteers, but also in the volatile bacterial 
metabolites that were detected in the stools that are considered potentially toxic 
for the liver (49). Similar results came from the recent study by Chierico et al in 
which 26 organic compounds including alcohols, acids, aldehydes, ketones, 
amines, and esters that result from microbial actions were upregulated in the 
feces of pediatric patients with NAFLD compared to controls (45). The same 
study apart from significantly lower levels of Oscillospira, found significantly 
higher levels of 1-pentanol and 2-butanone, (both volatile organic compounds) in 
NAFLD patients compared to controls indicating that high levels of 2-butanone 
and low relative abundance of Oscillospira could be a potential fecal biomarker 
profile for liver steatosis (45). 
Gut microbiota might also contribute to the development of NAFLD via the 
production of ethanol. Intestinal microbiota produces a number of potentially 
hepatotoxic substances including ethanol that are transported to the liver by the 
portal system. Acetaldehyde and acetate are two major metabolites of ethanol. 
Acetaldehyde and its metabolites may lead to the formation of reactive oxygen 
species that are implicated with liver injury, whereas the latter is a substrate for 
fatty acid synthesis (50) Nair et al observed higher breath ethanol concentrations 
in obese women than in leaner ones (15). A study by Zhu et al performed in 
pediatric population showed evidence of higher ethanol blood levels and higher 
abundance of alcohol-producing bacteria in the gut of subjects with NASH 
compared to healthy controls, thereby supporting a possible role for alcohol-
producing microbiota in the pathogenesis of NASH (51). This hypothesis could 
explain the similarities with regard to histological and biochemical findings that 
are present between alcoholic and nonalcoholic liver disease (1). 
Choline is a component of cell membranes that is found in foods such as 
red meat and eggs but can be also endogenously synthesized. Ιn the liver, 
choline is used for the synthesis of VLDL. Therefore, choline deficiency resulting 
from decreased intake, could prevent synthesis and excretion of VLDL, leading to 
hepatic triglyceride accumulation and hepatic steatosis (52). It has been 
suggested that gut bacteria affect the bioavailability of dietary choline to the host 
and can therefore influence the organism’s need for choline (53). Spencer et al 
showed that manipulations in dietary choline affected the type of gut microbiota 
as well as the amount of liver fat and indicated that specific members of the 
microbial community could predict susceptibility to choline deficiency induced 
fatty liver disease (53). The composition of gut microbiota before the induction of 
a low-choline diet intervention correlated with the development of NAFL, thus 
suggesting that the combination of choline dietary deficiency with a specific gut 
microbiota subtype could contribute to the development of NAFLD (53). 
Butyrate, which is the basic bacteria derived SCFA, markedly increases 
epithelial cell proliferation and differentiation, and thus improves colonic barrier 
function in the normal gut (11). Patients with NAFLD have increased intestinal 
permeability, and this was associated with changes in normal small bowel 
microbiota and increased prevalence of small intestinal bacterial overgrowth (54). 
This phenomenon may be associated with disruption of intercellular tight 
junctions of the intestine (54). Duca showed that mice on high fat feeding but not 
chow feeding, OP and the OP microbe recipient animals both exhibited altered 
tight junction protein levels indicating an impaired mucosal barrier (35). A recent 
study by Rahman et al performed in mice provided significant evidence that 
intestinal epithelial barrier dysfunction and microbial dysbiosis contribute to 
development of NASH (55). They showed that mice with disruption of the gene 
(F11r) encoding junctional adhesion molecule fed on diet high in saturated fat, 
fructose, and cholesterol (HFCD) for 8 weeks developed typical histologic 
features of severe NASH. In addition, this diet led to significant increase in 
inflammatory microbial taxa in F11r-/-, compared with control mice. Liver injury 
was also associated with significant increases in mucosal inflammation, tight 
junction disruption, and intestinal epithelial permeability to bacterial endotoxins 
(55). In this mouse model, a high calorie diet provided the first ‘hit’ favoring a pro-
inflammatory gut microbial composition, which exacerbated gut permeability. In 
turn, enhanced gut leakiness resulted in microbial product translocation, which 
induced hepatic inflammation and injury ultimately resulting in the progression of 
NAFLD to NASH (55).  
 NAFLD and therapeutic interventions in gut microbiota 
In view of a potentially beneficial role in NAFLD, therapeutic interventions 
in gut microbiota have attracted great research interest. As mentioned above, gut 
microbiota may influence energy harvest and affect satiety. Given these roles, 
randomized studies performed both in adults and children have investigated the 
role of probiotics and have shown promising results. Probiotics are live 
microorganisms that provide health benefit to the host when administered in 
adequate amounts by influencing the intestinal microbial ecology (56). A prebiotic 
is a nonviable food component that confers a health benefit on the host 
associated with modulation of the microbiota, (i.e. a fiber). The synergistic 
combination of prebiotics and probiotics is described as synbiotic (56). 
Modulations of the gut microbiota with the use of probiotics and/or symbiotics can 
result in adaptations in regulating gut hormones and thereby reduce energy 
harvest, enhance the feeling of satiety, improve glucose metabolism and also 
improve gut barrier function and thereby ameliorate endotoxaemia and 
inflammation that are often found in obesity and type 2 diabetes (11).  
A study by Cano et al performed in mice suggested that the administration 
of B. pseudocatenulatum in high fat diet-fed mice reduced hepatic steatosis (57). 
In addition, it reduced serum cholesterol, triglyceride, and glucose levels, 
decreased insulin resistance and improved glucose tolerance (57).    
In a randomized trial including 20 patients with biopsy proven NASH, a 6-
month course of a lactobacillus based formula improved steatosis and AST levels 
(58). The use of a probiotic yogurt containing Lactobacillus acidophilus La5 and 
Bifidobacterium lactis Bb12 for 28 weeks resulted in improved liver enzymes in a 
randomized trial of 38 patients with NAFLD (59).  A small randomized trial of 30 
patients with NAFLD evaluating a preparation of Lactobacillus bulgaricus and 
Streptococcus thermophiles administered for 3 months demonstrated an 
improvement in ALT levels (60). Similarly, a randomized controlled trial that 
included 38 subjects with metabolic syndrome, showed that a 28 week course of 
symbiotic therapy containing 200 million of seven strains of “friendly” bacteria 
resulted in significant improvement in liver biochemical tests and in various 
inflammatory markers (61). 
A randomized trial in 48 children with histologically proven NAFLD, 
showed that a 4-month probiotic therapy with VSL#3 resulted in a significant 
improvement of ultrasonographic findings (17). Another randomized controlled 
study that included 22 children, showed that probiotic treatment with the 
Lactobacillus rhamnosus strain GG for 8 weeks improved ALT levels, but 
failed to improve ultrasonographic findings (62).  
Although short term randomized trials have shown some promising results 
in the use of probiotics in the treatment of NAFLD, considering the longstanding 
course of the disease, larger long-term studies with appropriate histological 
outcomes are essential. Moreover, standardization of the probiotic composition 
and dose is required for meaningful conclusions.  
 
Conclusions 
Gut microbiota play a very important role in the homeostasis of human 
organism as they produce substances that serve as nutrient products, regulate 
energy harvest and contribute to vitamin biosynthesis and bile acid degradation. 
By affecting the secretion of gut hormones, microbiota can target multiple organs 
including the pancreas and the brain and thus contribute in insulin secretion, 
glucose regulation and satiety. Intestinal hormones are produced by the entero-
endocrine cells, in response to nutritional and hormonal signals and regulate 
multiple biological functions. GLP-1 has a beneficial role in homeostasis by 
increasing insulin secretion and promoting euglucemia. Recent evidence 
suggests that GLP agonists could be beneficial in the treatment of NAFLD. Apart 
from GLP-1, GLP-2 and PYY are also intestinal hormones that improve insulin 
secretion and energy homeostasis whereas ghrelin has an opposite role by 
acting as a pro hunger hormone. The association of specific types of gut 
microbiota with obesity and NAFLD is still under investigation. Most studies 
indicate different populations of microbiota between lean and obese people as 
well as among different phenotypes of NAFLD. Available data from both animal 
and human studies suggest that a causative link of gut microbiota in NAFLD 
could be present though multiple mechanisms including increased energy 
harvest, affected intestinal barrier, production of ethanol and impaired choline 
metabolism.  However, further long-term studies are necessary in order to 
confirm this conclusion, which in turn could further attract interest in the 
manipulation of the gut microbiome as a possible therapeutic target for the 
management of NAFLD. Available studies that mostly include probiotics have 
shown encouraging results. However, larger long-term studies that would ideally 
include histologic confirmation of improvement in NAFLD are necessary in order 
to confirm the beneficial role of this approach.  
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Figure 1. Intestinal hormones and their effects on metabolism.  
Intestinal hormones are produced by the enteroendocrine (EEC) cells located in 
the gastro-intestinal system, in response to nutritional and hormonal signals. 
Products derived from intestinal bacterial metabolism can further influence their 
secretion. Some of these hormones act with an antagonistic effect: GLP-1 
improves oral glucose tolerance and insulin sensitivity by increasing glucose-
dependent insulin secretion and promoting augmentation of pancreatic β-cell 
mass. Conversely, ghrelin increases adiposity and decreases insulin while 
stimulating glucagon secretion in the pancreas.  GLP-1 reduces gastric emptying 
and GI motility, mainly via vagal-mediated mechanisms, and targets the brain by 
stimulating satiety and thus decreasing food intake. Ghrelin also acts on the 
nervous system but has an orexigenic effect and stimulates gastric emptying. 
There is evidence supporting that GLP-1 could have a beneficial effect on 
NAFLD development and progression, while products of the ghrelin gene may be 
involved in the pathogenesis of NASH and fibrosis. GLP-2 maintains the 
intestinal barrier by inducing intestinal epithelial cell proliferation and increasing 
the production of intestinal tight junction proteins. 
Abbreviations: EEC, enteroendocrine cells; SCFA, short chain fatty acids; GLP-1, 
glucagon-like peptide 1; GLP-2, glucagon-like peptide 2. 
 
